{"id":"jskn016-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thus enhancing the immune response against cancer cells.","oneSentence":"JSKN016 injection is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:57:36.564Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07475559","phase":"PHASE1","title":"JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2026-03-01","conditions":"Advanced Solid Tumor Malignancies","enrollment":42},{"nctId":"NCT06868732","phase":"PHASE1","title":"Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-03-12","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":288},{"nctId":"NCT06592417","phase":"PHASE1","title":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2024-04-30","conditions":"Advanced Malignant Solid Tumor","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"JSKN016 injection","genericName":"JSKN016 injection","companyName":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","companyId":"jiangsu-alphamab-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JSKN016 injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}